Insulin B chain 9-23 gene transfer to hepatocytes protects from type 1 diabetes by inducing Ag-specific FoxP3+ Tregs

Science Translational Medicine

Volumn 7, Issue 289, 2015, Pages

  Akbarpour, Mahzad ^a,b   Goudy, Kevin S ^a   Cantore, Alessio ^a   Russo, Fabio ^a   Sanvito, Francesca ^c   Naldini, Luigi ^a,b   Annoni, Andrea ^a   Roncarolo, Maria Grazia ^a,b,d  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INSULIN; INSULIN B CHAIN 9 23; INTERLEUKIN 10; LENTIVIRUS VECTOR; MONOCLONAL ANTIBODY CD3; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; INSULIN B (9-23); INTEGRASE; PEPTIDE FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL INFILTRATION; CELL PROTECTION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GENE TARGETING; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IN VITRO GENE TRANSFER; INSB9 23 GENE; INSULIN DEPENDENT DIABETES MELLITUS; LIVER CELL; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; ANIMAL; CYTOTOXIC T LYMPHOCYTE; DIABETES MELLITUS, TYPE 1; DISEASE COURSE; GENE TRANSFER; GENE VECTOR; GENETICS; IMMUNOLOGY; LENTIVIRINAE; LIVER; METABOLISM; PATHOLOGY;

ANIMALS; ANTIGENS; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; FORKHEAD TRANSCRIPTION FACTORS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEPATOCYTES; IMMUNE TOLERANCE; INSULIN; INTEGRASES; LENTIVIRUS; LIVER; MICE; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TRANSGENES;

EID: 84930152813     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaa3032     Document Type: Article

References (71)

1. R. Tisch, H. McDevitt, Insulin-dependent diabetes mellitus. Cell 85, 291-297 (1996).
2. M. Anderson, J. Bluestone, The NOD mouse: A model of immune dysregulation. Annu. Rev. Immunol. 23, 447-485 (2005).
3. + T cells from glutamic acid decarboxylase (GAD)65-specific T cell receptor transgenic mice are not diabetogenic and can delay diabetes transfer. J. Exp. Med. 196, 481-492 (2002).
4. + T cells in human subjects. J. Immunol. 176, 2781-2789 (2006).
5. B. Stadinski, T. Delong, N. Reisdorph, R. Reisdorph, R. L. Powell, M. Armstrong, J. D. Piganelli, G. Barbour, B. Bradley, F. Crawford, P. Marrack, S. K. Mahata, J. W. Kappler, K. Haskins, Chromogranin A is an autoantigen in type 1 diabetes. Nat. Immunol. 11, 225-231 (2010).
6. + T cell-recognized autoantigen in pediatric type 1 diabetes. Diabetes 61,1779-1784 (2012).
7. A. Skowera, R. J. Ellis, R. Varela-Calvino, S. Arif, G. C. Huang, C. Van-Krinks, A. Zaremba, C. Rackham, J. S. Allen, T. I. M. Tree, M. Zhao, C. M. Dayan, A. K. Sewell, W. Unger, J. W. Drijfhout, F. Ossendorp, B. O. Roep, M. Peakman, CTLs are targeted to kill β cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J. Clin. Invest. 118, 3390-3402 (2008).
8. V. R. Sutton, E. Estella, C. Li, M. Chen, H. E. Thomas, T. W. Kay, J. A. Trapani, A critical role for granzyme B, in addition to perforin and TNFα, in alloreactive CTL-induced mouse pancreatic beta cell death. Transplantation 81, 146-154 (2006).
9. M.-G. Roncarolo, M. Battaglia, Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat. Rev. Immunol. 7, 585-598 (2007).
10. + T cells with limited suppressor activity. Eur. J. Immunol. 41, 1480-1490 (2011).
11. +regulatory T-cells in type 1 diabetes. Diabetes 56, 604-612 (2007).
12. M. Belghith, J. A. Bluestone, S. Barriot, J. Mégret, J. F. Bach, L. Chatenoud, TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. 9, 1202-1208 (2003).
13. C. Kuhn, S. You, F. Valette, G. Hale, P. van Endert, J. F. Bach, H. Waldmann, L. Chatenoud, Human CD3 transgenic mice: Preclinical testing of antibodies promoting immune tolerance. Sci. Transl. Med. 3, 68ra10 (2011).
14. L. Lazar, R. Ofan, N. Weintrob, A. Avron, M. Tamir, D. Elias, M. Phillip, Z. Josefsberg, Heatshock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: A randomised, double-blind phase II study. Diabetes Metab. Res. Rev. 23, 286-291 (2007).
15. J. S. Skyler, R. S. Weinstock, P. Raskin, J. F. Yale, E. Barrett, J. E. Gerich, H. C. Gerstein; Inhaled Insulin Phase III Type 1 Diabetes Study Group, Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: A 6-month, randomized, comparative trial. Diabetes Care 28, 1630-1635 (2005).
16. K. Näntö-Salonen, A. Kupila, S. Simell, H. Siljander, T. Salonsaari, A. Hekkala, S. Korhonen, R. Erkkola, J. I. Sipilä, L. Haavisto, M. Siltala, J. Tuominen, J. Hakalax, H. Hyöty, J. Ilonen, R. Veijola, T. Simell, M. Knip, O. Simell, Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: A double-blind, randomised controlled trial. Lancet 372, 1746-1755 (2008).
17. J. Ludvigsson, M. Faresjö, M. Hjorth, S. Axelsson, M. Chéramy, M. Pihl, O. Vaarala, G. Forsander, S. Ivarsson, C. Johansson, A. Lindh, N. O. Nilsson, J. Aman, E. Ortqvist, P. Zerhouni, R. Casas, GAD treatment and insulin secretion in recent-onset type 1 diabetes. N. Engl. J. Med. 359, 1909-1920 (2008).
18. F. Mingozzi, Y. L. Liu, E. Dobrzynski, A. Kaufhold, J. H. Liu, Y. Wang, V. R. Arruda, K. A. High, R. W. Herzog, Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J. Clin. Invest. 111, 1347-1356 (2003).
19. I. Crispe, The liver as a lymphoid organ. Annu. Rev. Immunol. 27, 147-163 (2009).
20. A. Thomson, P. Knolle, Antigen-presenting cell function in the tolerogenic liver environment. Nat. Rev. Immunol. 10, 753-766 (2010).
21. I. N. Crispe, Hepatic T cells and liver tolerance. Nat. Rev. Immunol. 3, 51-62 (2003).
22. E. Breous, S. Somanathan, L. Vandenberghe, J. M. Wilson, Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver. Hepatology 50, 612-621 (2009).
23. + regulatory T cells. Hepatology 42, 193-199 (2005).
24. G. Jiang, H.-R. Yang, L. Wang, G. M. Wildey, J. Fung, S. Qian, L. Lu, Hepatic stellate cells preferentially expand allogeneic CD4+ CD25+ FoxP3+ regulatory T cells in an IL-2-dependent manner. Transplantation 86, 1492-1502 (2008).
25. - regulatory T cells suppressing autoimmune hepatitis. Hepatology 50, 1904-1913 (2009).
26. B. D. Brown, A. Cantore, A. Annoni, L. S. Sergi, A. Lombardo, P. DellaValle, A. D'Angelo, L. Naldini, A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood 110, 4144-4152 (2007).
27. B. D. Brown, M. A. Venneri, A. Zingale, L. Sergi Sergi, L. Naldini, Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat. Med. 12, 585-591 (2006).
28. A. Annoni, B. D. Brown, A. Cantore, L. S. Sergi, L. Naldini, M. G. Roncarolo, In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance. Blood 114, 5152-5161 (2009).
29. J. Mátrai, A. Cantore, C. C. Bartholomae, A. Annoni, W. Wang, A. Acosta-Sanchez, E. Samara-Kuko, L. De Waele, L. Ma, P. Genovese, M. Damo, A. Arens, K. Goudy, T. C. Nichols, C. von Kalle, M. K. L. Chuah, M. G. Roncarolo, M. Schmidt, T. Vandendriessche, L. Naldini, Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk. Hepatology 53, 1696-1707 (2011).
30. A. Annoni, A. Cantore, P. Della Valle, K. Goudy, M. Akbarpour, F. Russo, S. Bartolaccini, A. D'Angelo, M. G. Roncarolo, L. Naldini, Liver gene therapy by lentiviral vectors reverses anti-factor IX preexisting immunity in haemophilic mice. EMBO Mol. Med. 5, 1684-1697 (2013).
31. L. Chatenoud, E. Thervet, J. Primo, J. F. Bach, Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl. Acad. Sci. U.S.A. 91, 123-127 (1994).
32. D. S. Mehta, R. A. Christmas, H. Waldmann, M. Rosenzweig, Partial and transient modulation of the CD3-T cell receptor complex, elicited by low dose regimens of monoclonal anti CD3, is sufficient to induce disease remission in non obese diabetic mice. Immunology 130, 103-113 (2010).
33. + T-cell clones derived from lymphocytes infiltrating the islets of NOD mice. Diabetes 41, 998-1008 (1992).
34. E. Montini, D. Cesana, M. Schmidt, F. Sanvito, M. Ponzoni, C. Bartholomae, L. Sergi Sergi, F. Benedicenti, A. Ambrosi, C. Di Serio, C. Doglioni, C. von Kalle, L. Naldini, Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 24, 687-696 (2006).
35. A. Biffi, C. Bartolomae, D. Cesana, N. Cartier, P. Aubourg, M. Ranzani, M. Cesani, F. Benedicenti, T. Plati, E. Rubagotti, S. Merella, A. Capotondo, J. Sgualdino, G. Zanetti, C. von Kalle, M. Schmidt, L. Naldini, E. Montini, Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood 117, 5332-5339 (2011).
36. A. Aiuti, L. Biasco, S. Scaramuzza, F. Ferrua, M. P. Cicalese, C. Baricordi, F. Dionisio, A. Calabria, S. Giannelli, M. C. Castiello, M. Bosticardo, C. Evangelio, A. Assanelli, M. Casiraghi, S. Di Nunzio, L. Callegaro, C. Benati, P. Rizzardi, D. Pellin, C. Di Serio, M. Schmidt, C. Von Kalle, J. Gardner, N. Mehta, V. Neduva, D. J. Dow, A. Galy, R. Miniero, A. Finocchi, A. Metin, P. P. Banerjee, J. S. Orange, A. Galimberti, M. G. Valsecchi, A. Biffi, E. Montini, A. Villa, F. Ciceri, M. G. Roncarolo, L. Naldini, Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341, 1233151 (2013).
37. A. Biffi, E. Montini, L. Lorioli, M. Cesani, F. Fumagalli, T. Plati, C. Baldoli, S. Martino, A. Calabria, S. Canale, F. Benedicenti, G. Vallanti, L. Biasco, S. Leo, N. Kabbara, G. Zanetti, W. B. Rizzo, N. A. Mehta, M. P. Cicalese, M. Casiraghi, J. J. Boelens, U. Del Carro, D. J. Dow, M. Schmidt, A. Assanelli, V. Neduva, C. Di Serio, E. Stupka, J. Gardner, C. von Kalle, C. Bordignon, F. Ciceri, A. Rovelli, M. G. Roncarolo, A. Aiuti, M. Sessa, L. Naldini, Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341, 1233158 (2013).
38. 500 autoantigen by AAV serotype 1 prevented diabetes in NOD mice: Transduction efficiency do not play important roles. Immunol. Lett. 115, 110-116 (2008).
39. + cell populations in vivo and ameliorates type 1 diabetes in nonobese diabetic mice in a dose-dependent fashion. J. Immunol. 171, 2270-2278 (2003).
40. K. S. Goudy, M. C. Johnson, A. Garland, C. Li, R. J. Samulski, B. Wang, R. Tisch, Inducible adeno-associated virus-mediated IL-2 gene therapy prevents autoimmune diabetes. J. Immunol. 186, 3779-3786 (2011).
41. Y. Chang, S. Yap, X. Ge, J. Piganelli, S. Bertera, N. Giannokakis, C. Mathews, G. Prud'homme, M. Trucco, DNA vaccination with an insulin construct and a chimeric protein binding to both CTLA4 and CD40 ameliorates type 1 diabetes in NOD mice. Gene Ther. 12, 1679-1685 (2005).
42. A. Bot, D. Smith, S. Bot, A. Hughes, T. Wolfe, L. Wang, C. Woods, M. von Herrath, Plasmid vaccination with insulin B chain prevents autoimmune diabetes in nonobese diabetic mice. J. Immunol. 167, 2950-2955 (2001).
43. D. Bresson, M. Fradkin, Y. Manenkova, D. Rottembourg, M. von Herrath, Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetes. Mol. Ther. 18, 307-316 (2010).
44. B. O. Roep, N. Solvason, P. A. Gottlieb, J. R. F. Abreu, L. C. Harrison, G. S. Eisenbarth, L. Yu, M. Leviten, W. A. Hagopian, J. B. Buse, M. von Herrath, J. Quan, R. S. King, W. H. Robinson, P. J. Utz, H. Garren, Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8+ T cells in type 1 diabetes. Sci. Transl. Med. 5, 191ra82 (2013).
45. J. Machen, J. Harnaha, R. Lakomy, A. Styche, M. Trucco, N. Giannoukakis, Antisense oligo-nucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J. Immunol. 173, 4331-4341 (2004).
46. S. Lüth, S. Huber, C. Schramm, T. Buch, S. Zander, C. Stadelmann, W. Brück, D. C. Wraith, J. Herkel, A. W. Lohse, Ectopic expression of neural autoantigen in mouse liver suppresses experimental autoimmune neuroinflammation by inducing antigen-specific Tregs. J. Clin. Invest. 118, 3403-3410 (2008).
47. L. Harrison, M. Dempsey-Collier, D. Kramer, K. Takahashi, Aerosol insulin induces regulatory CD8 γδ T cells that prevent murine insulin-dependent diabetes. J. Exp. Med. 184, 2167-2174 (1996).
48. D. Daniel, D. Wegmann, Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc. Natl. Acad. Sci. U.S.A. 93, 956-960 (1996).
49. G. Fousteri, A. Dave, A. Bot, T. Juntti, S. Omid, M. von Herrath, Subcutaneous insulin B:9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNγ. Diabetologia 53, 1958-1970 (2010).
50. I. Urbanek-Ruiz, P. Ruiz, V. Paragas, H. Garren, L. Steinman, C. G. Fathman, Immunization with DNA encoding an immunodominant peptide of insulin prevents diabetes in NOD mice. Clin. Immunol. 100, 164-171 (2001).
51. E. Liu, H. Moriyama, N. Abiru, D. Miao, L. Yu, R. M. Taylor, F. D. Finkelman, G. S. Eisenbarth, Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9-23 and B:13-23. J. Clin. Invest. 110, 1021-1027 (2002).
52. Y. Glinka, Y. Chang, G. Prud'homme, Protective regulatory T cell generation in autoimmune diabetes by DNA covaccination with islet antigens and a selective CTLA-4 ligand. Mol. Ther. 14, 578-587 (2006).
53. B. Poligone, D. Weaver Jr., P. Sen, A. S. Baldwin Jr., R. Tisch, Elevated NF-κB activation in nonobese diabetic mouse dendritic cells results in enhanced APC function. J. Immunol. 168, 188-196 (2002).
54. K. S. Goudy, A. Annoni, L. Naldini, M. G. Roncarolo, Manipulating immune tolerance with micro-RNA regulated gene therapy. Front. Microbiol. 2, 221 (2011).
55. A. Annoni, K. Goudy, M. Akbarpour, L. Naldini, M. G. Roncarolo, Immune responses in liver-directed lentiviral gene therapy. Transl. Res. 161, 230-240 (2013).
56. L. E. Holz, A. Warren, D. G. Le Couteur, D. G. Bowen, P. Bertolino, CD8+ T cell tolerance following antigen recognition on hepatocytes. J. Autoimmun. 34,15-22 (2010).
57. J. Bluestone, Q. Tang, C. Sedwick, T regulatory cells in autoimmune diabetes: Past challenges, future prospects. J. Clin. Immunol. 28, 677-684 (2008).
58. S. Weber, J. Harbertson, E. Godebu, G. A. Mros, R. C. Padrick, B. D. Carson, S. F. Ziegler, L. M. Bradley, Adaptive islet-specific regulatory CD4 T cells control autoimmune diabetes and mediate the disappearance of pathogenic Th1 cells in vivo. J. Immunol. 176, 4730-4739 (2006).
59. X. Luo, K. V. Tarbell, H. Yang, Dendritic cells with TGF-beta1 differentiate naive CD4+CD25-T cells into islet-protective Foxp3+ regulatory T cells. Proc. Natl. Acad. Sci. U.S.A. 104, 2821-2826 (2007).
60. Q. Tang, K. Henriksen, M. Bi, E. Finger, G. Szot, J. Ye, E. Masteller, H. McDevitt, M. Bonyhadi, J. Bluestone, In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 199, 1455-1465 (2004).
61. S. Tsai, A. Shameli, J. Yamanouchi, X. Clemente-Casares, J. Wang, P. Serra, Y. Yang, Z. Medarova, A. Moore, P. Santamaria, Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity 32, 568-580 (2010).
62. J. D. Katz, B. Wang, K. Haskins, C. Benoist, D. Mathis, Following a diabetogenic T cell from genesis through pathogenesis. Cell 74, 1089-1100 (1993).
63. S. Prasad, A. Kohm, J. McMahon, X. Luo, S. D. Miller, Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading. J. Autoimmun. 39, 347-353 (2012).
64. Y. Grinberg-Bleyer, D. Saadoun, A. Baeyens, F. Billiard, J. D. Goldstein, S. Grégoire, G. H. Martin, R. Elhage, N. Derian, W. Carpentier, G. Marodon, D. Klatzmann, E. Piaggio, B. L. Salomon, Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. J. Clin. Invest. 120, 4558-4568 (2010).
65. M. Banasik, P. McCray Jr., Integrase-defective lentiviral vectors: Progress and applications. Gene Ther. 17, 150-157 (2010).
66. B. Tait, L. Harrison, B. Drummond, V. Stewart, M. D. Varney, M. C. Honeyman, HLA antigens and age at diagnosis of insulin-dependent diabetes mellitus. Hum. Immunol. 42, 116-122 (1995).
67. S. Bennett, A. Lucassen, S. Gough, E. E. Powell, D. E. Undlien, L. E. Pritchard, M. E. Merriman, Y. Kawaguchi, M. J. Dronsfield, F. Pociot, J. Nerup, N. Bouzekri, A. Cambon-Thomsen, K. S. Rønningen, A. H. Barnett, S. C. Bain, J. A. Todd, Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nat. Genet. 9, 284-292 (1995).
68. H. Ueda, J. M. Howson, L. Esposito, J. Heward, H. Snook, G. Chamberlain, D. B. Rainbow, K. M. D. Hunter, A. N. Smith, G. DiGenova, M. H. Herr, I. Dahlman, F. Payne, D. Smyth, C. Lowe, R. C. J. Twells, S. Howlett, B. Healy, S. Nutland, H. E. Rance, V. Everett, L. J. Smink, A. C. Lam, H. J. Cordell, N. M. Walker, C. Bordin, J. Hulme, C. Motzo, F. Cucca, J. F. Hess, M. L. Metzker, J. Rogers, S. Gregory, A. Allahabadia, R. Nithiyananthan, E. Tuomilehto-Wolf, J. Tuomilehto, P. Bingley, K. M. Gillespie, D. E. Undlien, K. S. Rønningen, C. Guja, C. Ionescu-Tîrgovite, D. A. Savage, A. P. Maxwell, D. J. Carson, C. C. Patterson, J. A. Franklyn, D. G. Clayton, L. B. Peterson, L. S. Wicker, J. A. Todd, S. C. L. Gough, Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423, 506-511 (2003).
69. N. Bottini, L. Musumeci, A. Alonso, S. Rahmouni, K. Nika, M. Rostamkhani, J. MacMurray, G. F. Meloni, P. Lucarelli, M. Pellecchia, G. S. Eisenbarth, D. Comings, T. Mustelin, A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat. Genet. 36, 337-338 (2004).
70. C. Verge, R. Gianani, E. Kawasaki, L. Yu, M. Pietropaolo, R. A. Jackson, H. P. Chase, G. S. Eisenbarth, Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 45, 926-933 (1996).
71. A. Follenzi, L. Naldini, HIV-based vectors. Preparation and use. Methods Mol. Med. 69, 259-274 (2002).